Status:

COMPLETED

Phase IIIb, Open-label, Multi-center Study to Evaluate Safety, Tolerability and Efficacy of OAV101 Administered Intrathecally to Participants With SMA Who Discontinued Treatment With Nusinersen or Risdiplam

Lead Sponsor:

Novartis Pharmaceuticals

Conditions:

Spinal Muscular Atrophy

Eligibility:

All Genders

2-17 years

Phase:

PHASE3

Brief Summary

This was a Phase IIIb open-label, single arm, multi-center study to evaluate the safety, tolerability and efficacy of OAV101B in participants with SMA aged 2 to \<18 years after the discontinuation of...

Detailed Description

Eligible participants received a single OAV101B administration of 1.2x1014 vector genomes on Day 1 (Treatment period) and were followed for a period of 52 weeks. Participants were admitted to the hos...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • SMA diagnosis
  • Aged 2 to \< 18 years
  • Have had at least four loading doses of nusinersen (Spinraza®) or at least 3 months of treatment with risdiplam (Evrysdi®) at Screening
  • Must have symptoms of SMA as defined in the protocol
  • Exclusion Criteria:
  • Anti Adeno Associated Virus Serotype 9 (AAV9) antibody titer using an immunoassay is reported as elevated
  • Clinically significant abnormalities in test results during screening
  • Contraindications for lumbar puncture procedure
  • At Baseline, participants are excluded if they received:
  • nusinersen (Spinraza®) or
  • risdiplam (Evrysdi®) within a defined timeframe
  • Vaccinations 2 weeks prior to administration of OAV101
  • Hospitalization for a pulmonary event, or for nutritional support within 2 months prior to Screening or inpatient major surgery planned.
  • Presence of an infection or febrile illness up to 30 days prior to administration of OAV101
  • Requiring invasive ventilation

Exclusion

    Key Trial Info

    Start Date :

    January 12 2023

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 29 2024

    Estimated Enrollment :

    27 Patients enrolled

    Trial Details

    Trial ID

    NCT05386680

    Start Date

    January 12 2023

    End Date

    November 29 2024

    Last Update

    October 16 2025

    Active Locations (13)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 4 (13 locations)

    1

    Boston Childrens Hospital

    Boston, Massachusetts, United States, 02215

    2

    Child Hosp Of The Kings Daughters

    Norfolk, Virginia, United States, 23507

    3

    University of Wisconsin Madison Medical School

    Madison, Wisconsin, United States, 53792-7375

    4

    Novartis Investigative Site

    Parkville, Victoria, Australia, 3052